EKF Signs Distribution Deal with Diagnostica Peruana
As part of the distribution agreement, Diagnostica Peruana will deliver, install and maintain the Hemo-Control devices as well as providing instrument training to new users. EKF has worked with Diagnostica Peruana since 2008.
The contract with MINSA (the Health Ministry of Peru) is to purchase over 3,000 Hemo-Control devices over the next three months. A number of devices have already been delivered with the remainder being fulfilled during October and November 2010.
These will be delivered with two months worth of cuvettes. A further ongoing supply of cuvettes to MINSA is currently subject to tender but given the special design of the cuvettes required for the device EKF is confident that its tender will be successful during 2011. Any agreement for future cuvette supply is expected to be under a long term contract, added EKF Diagnostics.
The Hemo-Control device is designed for use in doctors' offices, blood donor centers and small clinics and works with specially designed cuvettes that perform haemoglobin tests with a calculated haematocrit from a single sample, added EKF Diagnostics.
According to the company, the device is quick and easy to use and can provide a precise determination of haemoglobin and haematocrit levels from a patient blood sample in under 30 seconds.
The Hemo-Control device is CE marked, as are all EKF products, and is also FDA approved and has a Clinical Laboratory Improvement Amendment (CLIA) waiver.
Julian Baines, CEO of EKF, said: “ This is a strategic contract win for EKF as the placement of such a large quantity of devices creates a foundation for other successful product sales in the Peruvian Point of Care market.
“With the global haemoglobin market estimated to be worth over $500m annually we are very well placed to increase our share of this, especially through expansion of our sales effort into one of the world's largest markets, the US.”
Will the deal benefit EKF?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.